Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside

Citations Over TimeTop 10% of 2018 papers

Abstract

Head and neck cancer represents the seventh most common cancer worldwide. Although multidisciplinary sequential treatments have been used, there is still an urgent need for new treatment approaches that can effectively improve the outcomes of patients with advanced stages of head and neck cancer. Gene therapy is a rapidly evolving field in cancer therapy that has been shown to improve the efficacy of antitumor treatment. China is at the forefront in clinical trials and practice of gene therapy. Chinese researchers have mainly focused on gene therapeutics based on oncolytic virus and recombinant adenovirus expressing p53, antiangiogenesis factor or herpes simplex virus-thymidine kinase. Currently, two gene therapy drugs, Gendicine and Oncorine, have been marketed in China, and a number of upcoming gene therapy agents are under development for the treatment of head and neck cancer. Most gene therapy agents have demonstrated excellent tolerance. However, the therapeutic effects need further improvement. With current innovations in tumor biology and knowledge, gene therapy has great potential as a safe and effective anticancer treatment. In recent years, new gene therapy agents with promising effects have been incorporated into clinical trials in China. Thus, gene therapy may become an important part of anticancer therapy and is expected to improve the therapeutic effect of head and neck cancers in the near future.

Related Papers

• → Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?(2015)29 cited
• Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.(2003)
• → Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy(2010)
• → A138(2015)
• Oncolytic herpes simplex virus and its advances in cancer therapy(2008)